Thursday, August 20, 2015
23andMe, a personal genetics company, has appointed Dean Schorno, CPA, as chief financial officer and head of operations. He will oversee 23andMe’s global financial and clinical laboratory operations. Schorno brings a wealth of experience to the job, most recently working as chief financial officer of Adaptive Biotechnologies.
The Biomedical Research Alliance of New York (BRANY), the developer of Protocol Builder, has appointed Christopher Olsen as senior director of national sales and marketing. Olsen will be responsible for sales and marketing efforts with academic medical centers, health systems, hospitals and individual clinical investigators.
Sagent Pharmaceuticals, a Schaumburg, Ill.-based provider of specialty pharmaceutical products with a specific emphasis on the injectables market, has named Allan Oberman chief executive officer and a member of the board of directors, effective immediately upon receipt of a U.S. work visa.
Epizyme, a clinical stage biopharmaceutical R&D company creating novel epigenetic therapeutics for cancer patients, has announced Robert Bazemore will succeed Robert Gould, Ph.D., as president and chief executive officer of Epizyme, effective Sept. 10. Bazemore also will join the Epizyme board of directors. Following the transition, Gould will continue to sit on the board and work as a consultant to the company.